Similar articles

• Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.

  Nishikawa M, Kanamori M, Hidaka H. Nishikawa M, et al. J Pharmacol Exp Ther. 1982 Jan;220(1):183-90. J Pharmacol Exp Ther. 1982. PMID: 6118429 No abstract available.
• Activation of cyclic nucleotide phosphodiesterase from isolated human peripheral blood lymphocytes by mitogenic agents.

  Epstein PM, Mills JS, Hersh EM, Strada SJ, Thompson WJ. Epstein PM, et al. Cancer Res. 1980 Feb;40(2):379-86. Cancer Res. 1980. PMID: 6243252 No abstract available.
• Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.

  Matsuoka I, Suzuki T. Matsuoka I, et al. J Cyclic Nucleotide Protein Phosphor Res. 1983;9(4-5):341-53. J Cyclic Nucleotide Protein Phosphor Res. 1983. PMID: 6147364
• Cyclic nucleotides and phosphodiesterases in platelets.

  Haslam RJ, Dickinson NT, Jang EK. Haslam RJ, et al. Thromb Haemost. 1999 Aug;82(2):412-23. Thromb Haemost. 1999. PMID: 10605732 Review. No abstract available.
• Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design.

  Sheth SB, Colman RW. Sheth SB, et al. Semin Hematol. 1995 Apr;32(2):110-9. Semin Hematol. 1995. PMID: 7652578 Review. No abstract available.